More than 80 diseases occur as a result of the immune system attacking the body’s own organs, tissues, and cells. Some of the more common autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.
Although the causes of many autoimmune diseases remain unknown, a person’s genes in combination with infections and other environmental exposures are likely to play a significant role in disease development. Treatments are available for many autoimmune diseases, but cures have yet to be discovered.
Why Is the Study of Autoimmune Diseases a Priority for NIAID?
The chronic and debilitating nature of these diseases, which can lead to high medical costs and reduced quality of life, is a burden on patients and also affects their families and communities.
How Is NIAID Addressing This Critical Topic?
Although researchers have made considerable progress in understanding how the immune system causes organ, tissue, and cell injury in autoimmune diseases, much remains to be learned. By supporting a broad range of basic, preclinical, and clinical research in autoimmune diseases, NIAID enhances understanding of the causes of these diseases, the genetic factors that make people susceptible to them, and the regulatory mechanisms that control the production of self-destructive antibodies.
NIAID-supported research on autoimmune diseases focuses on the immunologic basis of disease, including developing a greater understanding of the fundamental immunologic principles underlying disease onset and progression, developing improved animal models of disease, developing improved diagnostic tools, and identifying and evaluating more effective immune-based treatment and prevention strategies.
Latest News Releases
NIAID Now Blog
The AMP AIM Program
NIAID supports the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which launched in 2021 to deepen understanding of the cellular and molecular interactions that lead to inflammation and autoimmune diseases. AMP AIM investigators study rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and Sjögren’s disease to generate knowledge that will advance the development of new and enhanced treatments for autoimmune diseases.
NIAID and the National Institutes of Health (NIH) conduct ongoing clinical trials on autoimmune diseases. Read more about selected active clinical trials below: